A randomized double-blind study using CaNa2EDTA, a phospholipase A2 inhibitor, in the management of human acute pancreatitis.
In a randomized double-blind study the effect of CaNa2EDTA, a phospholipase A2 inhibitor, was tested as a treatment for acute pancreatitis. CaNa2EDTA was infused intravenously during the first 2 days after admission to hospital, in addition to normal conservative treatment. CaNa2EDTA decreased the serum phospholipase A2 activity and appeared to promote recovery from the illness. To what extent the inhibition of serum phospholipase activity may prevent the progress of severe haemorrhagic pancreatitis or diminish mortality and morbidity in acute pancreatitis should be investigated in further studies.
D000208:Acute Disease; D017302:Annexins; D002135:Calcium-Binding Proteins; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004492:Edetic Acid / Q000627:therapeutic use*; D005260:Female; D006023:Glycoproteins / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000188:drug therapy* / Q000378:metabolism; D010740:Phospholipases / Q000037:antagonists & inhibitors*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D011897:Random Allocation
D017302:Annexins; D002135:Calcium-Binding Proteins; D006023:Glycoproteins; C030958:lipomodulin; D004492:Edetic Acid; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2